Gastrointestinal cancer is one of the most common malignant tumors in China which affects people health seriously. Along with the investigation of the cancer molecular markers and the application of novel target agents, the therapeutic modalities for gastrointestinal cancers have been changing gradually. More and more target drugs, such as trastuzumab, cetuximab, bevacizumab,have been used in clinical practice. The individualized therapy based on the molecular classification will benefit more patients and is the inevitable trend of gastrointestinal cancer treatments in the future.